549 related articles for article (PubMed ID: 29799328)
1. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
3. Real-World Treatment Patterns and Costs for Patients with Renal Cell Carcinoma Initiating Treatment with Sunitinib and Pazopanib.
MacLean E; Mardekian J; Cisar LA; Hoang CJ; Harnett J
J Manag Care Spec Pharm; 2016 Aug; 22(8):979-90. PubMed ID: 27459661
[TBL] [Abstract][Full Text] [Related]
4. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
[TBL] [Abstract][Full Text] [Related]
5. Health care costs among renal cancer patients using pazopanib and sunitinib.
Hansen RN; Hackshaw MD; Nagar SP; Arondekar B; Deen KC; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Jan; 21(1):37-44, 44a-d. PubMed ID: 25562771
[TBL] [Abstract][Full Text] [Related]
6. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
[TBL] [Abstract][Full Text] [Related]
7. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
9. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.
MacLean E; Cisar L; Mehle K; Eremina D; Quigley JM
J Manag Care Spec Pharm; 2016 Jun; 22(6):723-732u. PubMed ID: 27231799
[TBL] [Abstract][Full Text] [Related]
10. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Hackshaw MD; Nagar SP; Parks DC; Miller LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
[TBL] [Abstract][Full Text] [Related]
11. Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
Racsa PN; Whisman TR; Worley K
Curr Med Res Opin; 2015; 31(10):1933-40. PubMed ID: 26368665
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data.
Sundaram M; Song Y; Rogerio JW; Zhang S; Bhattacharya R; Adejoro O; Carley C; Zhu JJ; Signorovitch J; Haas NB
J Manag Care Spec Pharm; 2022 Oct; 28(10):1149-1160. PubMed ID: 36048895
[No Abstract] [Full Text] [Related]
13. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects.
Smith MR; Sandhu S; George DJ; Chi KN; Saad F; Thiery-Vuillemin A; Stàhl O; Olmos D; Danila DC; Gafanov R; Castro E; Moon H; Joshua AM; Mason GE; Espina BM; Liu Y; Lopez-Gitlitz A; Francis P; Bevans KB; Fizazi K
J Manag Care Spec Pharm; 2023 Jul; 29(7):758-768. PubMed ID: 37404070
[No Abstract] [Full Text] [Related]
14. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
[No Abstract] [Full Text] [Related]
15. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
[TBL] [Abstract][Full Text] [Related]
16. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
[TBL] [Abstract][Full Text] [Related]
17. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
18. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
[No Abstract] [Full Text] [Related]
19. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968
[TBL] [Abstract][Full Text] [Related]
20. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]